BMD monitoring of bisphosphonate therapy not needed during first 3 years

Article

Postmenopausal women treated with alendronate may not need bone mineral density monitoring within the first 3 years of starting treatment because such tests can give misleading results, according to a study published online on June 23 in BMJ.

Postmenopausal women treated with alendronate may not need bone mineral density monitoring within the first 3 years of starting treatment because such tests can give misleading results, according to a study published online on June 23 in BMJ.

Katy J.L. Bell, of the University of Sydney in Australia, and colleagues conducted a trial of 6,459 postmenopausal women with low bone mineral density who were randomized to receive either placebo or the bisphosphonate alendronate, and who were followed up to undergo hip and spine bone density measurements 1, 2, and 3 years later.

After 3 years of treatment, hip bone mineral density increased by a mean .030 g/cm2 and treatment gave 97.5% of patients an increase of at least .019 g/cm2, the researchers found. But even though the researchers found that the effects of the drug varied between individuals during the first 3 years of treatment, the size of the variation wasn’t clinically significant, which prompted them to conclude that BMD monitoring wouldn’t reveal anything significant for individual patients.

“Clinicians may cite other reasons for monitoring besides estimating the intended effects of treatment,” the authors write. “One common reason given is to assess adherence to treatment. However, the large background within-person variation for bone mineral density means that monitoring is unlikely to give reliable information about whether the drugs were taken as prescribed.”

The study was supported by Merck. Authors reported relationships with Merck and other pharmaceutical companies.

Bell KJ, Hayen A, Macaskill P, et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ. 2009;338:b2266. doi: 10.1136/bmj.b2266.

Related Videos
Why doxycycline PEP lacks clinical data for STI prevention in women
The importance of nipocalimab’s FTD against FNAIT | Image Credit:  linkedin.com
Enhancing cervical cancer management with dual stain | Image Credit: linkedin.com
Fertility treatment challenges for Muslim women during fasting holidays | Image Credit: rmanetwork.com
Understanding the impact of STIs on young adults | Image Credit: providers.ucsd.edu.
CDC estimates of maternal mortality found overestimated | Image Credit: rwjms.rutgers.edu.
Study unveils maternal mortality tracking trends | Image Credit: obhg.com
How Harmonia Healthcare is revolutionizing hyperemesis gravidarum care | Image Credit: hyperemesis.org
Unveiling gender disparities in medicine | Image Credit:  findcare.ahn.org.
Exploring the intersection of heart health and women's health | Image Credit: cedars-sinai.org
Related Content
© 2024 MJH Life Sciences

All rights reserved.